when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Fierce Biotech·5h ago·1 min read

The future of RAS inhibitors

Sep 11, 2026·read at Fierce Biotech ↗

Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach of RAS-targeting drugs.

source

Reporting by Fierce Biotech.

read at Fierce Biotech ↗

sharex / twitter linkedin

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

15h agoIn first interview as FDA oncology chief, Angelo de Claro vows to ‘continue the innovation’ behind OCE legacyFierce Biotech
17h agoSingapore launches biotech-focused Boston hub to build on 'centuries-old bond'Fierce Biotech
19h agoScientists boycott American Diabetes Association as fallout of June conference fracas escalatesFierce Biotech
1d agoChutes & Ladders—Longtime Takeda R&D chief to depart next JuneFierce Biotech
1d agoNovartis shareholder calls for board overhaul following costly deal setbacks: ReutersFierce Biotech